Rajiv Patni Reata Pharmaceuticals Inc (RETA) insider trading activity

RETA Quotes by TradingView

Rajiv Patni is EVP, Chief R&D Officer of REATA PHARMACEUTICALS INC. Currently has a direct ownership of 0 shares of RETA, which is worth approximately $0. The most recent transaction as insider was on Sep 26, 2023, when has been sold 45,000 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
100.0% 12M change
Total Value Held $0

Rajiv Patni Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 26 2023
SELL
Sale (or disposition) back to the issuer
-
45,000 Reduced 100.0%
0 Class A Common Stock
Jun 12 2023
BUY
Grant, award, or other acquisition
-
45,000 Added 50.0%
45,000 Class A Common Stock

Also insider at

CRTX
Cortexyme, Inc. Healthcare
RP

Rajiv Patni

EVP, Chief R&D Officer
Plano, TX

Track Institutional and Insider Activities on RETA

Follow REATA PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RETA shares.

Notify only if

Insider Trading

Get notified when an Reata Pharmaceuticals Inc insider buys or sells RETA shares.

Notify only if

News

Receive news related to REATA PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on RETA